An Open Label, Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative (ER, PR, and HER-2 Negative) Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 14 Sep 2017
At a glance
- Drugs Veliparib (Primary) ; Lapatinib
- Indications Breast cancer
- Focus Adverse reactions
- 09 Sep 2017 Planned End Date changed from 1 Jun 2018 to 1 Oct 2018.
- 09 Sep 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Oct 2017.
- 09 Sep 2017 Status changed from recruiting to active, no longer recruiting.